Nanoparticulate formulations for paclitaxel delivery across MDCK cell monolayer

Current Pharmaceutical Design

Volumn 16, Issue 21, 2010, Pages 2331-2340

  Xie, Jingwei ^a   Lei, Chenlu ^a   Hu, Yong ^b   Gay, Gary Kaizhong ^a   Jamali, Nazrul Hadi Bin ^a   Wang, Chi Hwa ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NANJING UNIVERSITY   (China)

Author keywords

Blood brain barrier; Cancer chemotherapy; Coating; MDCK; Nanoparticles

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALPHA TOCOPHEROL; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; POLYSORBATE 80; SURFACTANT; TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG TRANSPORT; DRUG UPTAKE; ELECTRIC RESISTANCE; ENCAPSULATION; GLIOMA CELL; IN VITRO STUDY; MONOLAYER CULTURE; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURFACE PROPERTY; TRANSENDOTHELIAL ELECTRICAL RESISTANCE;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOGS; DRUG DELIVERY SYSTEMS; LACTIC ACID; NANOPARTICLES; PACLITAXEL; POLYGLYCOLIC ACID;

EID: 77955629588     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791920432     Document Type: Article

References (56)

1. Rowinsky EK, Wright M, Monsarrat B, et al. Taxol: Pharmacology, metabolism and clinical implications. Cancer Surveys 1993; 17: 283-301.
2. Mcguire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelia neoplasms. Ann Intern Med 1989; 111: 273-9.
3. Holmes FA, Walters RS, Theriault RL, et al. Phase IItrials of taxol, an active drug in the treatment of metastatic breast cancer. Natl Cancer Inst 1991; 83: 1797-805.
4. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002; 235: 179-92.
5. Cahan MA, Walter KA, Colvin OM, et al. Cytotoxicity of Taxol in vitro against human and rat malignant brain tumours. Cancer Chemother Pharmacol 1994; 33: 441-4.
6. Fellner S, Bauer B, Miller DS, et al. Transport of Paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002; 10: 1309-17.
7. Klecker R, Jamis-Dow C, Egorin M, et al. Distribution and metabolism of 3H-Taxol in the rat. Proc Am Assoc Cancer Res 1993; 34: 380.
8. Heimans JJ, Vermorken JB, Wolbers JG, et al. Paclitaxel (Taxol) concentrations in brain tumor tissue. Ann Oncol 1994; 5: 951-3.
9. Polli JW, Humphreys JE, Wring SA, et al. A comparison of Madin-Darby canine kidney cells and bovine brain endothelial cells as a blood-brain barrier screen in early drug discovery. In: Balls M, van Zeller AM, Halder ME, Eds. Progress in the reduction, refinement and replacement of animal experimentation. Amsterdam: Elsevier Sciences, 2000; pp. 271-89.
10. Lundquist S, Renftel M. The use of in vitro cell culture models for mechanistic studies and as permeability screens for the blood-brain barrier in the pharmaceutical industry-background and current status in the drug discovery process. Vasc Pharmacol 2002; 38: 355-64.
11. Cho MJ, Thompson DP, Cramer CT, et al. The madin darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharm Res 1989; 3: 71-7.
12. Veronsi B. Characterization of the MDCK cell line for screening neurotoxicants. Neurotoxicology 1996; 17: 433-43.
13. Salem H, Katz SA. Advances in animal alternatives for safety and efficacy testing. Wahsington D. C.: Taylor & Francis 1998; pp. 243-50.
14. Sawada GA, Barsuhn CL, Lutzke BS, et al. Increased lipophilicity and subsequent cell partitioning decrease passive transcellular diffusion of novel, highly lipophilic antioxidants. J Pharmacol Exp Ther 1999; 288: 1317-26.
15. Mahar Doan KM, Humphreys JE, Webster LO, et al. Passive permeability and p-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 2002; 303: 1029-37.
16. Wang Q, Rager JD, Weinstein K, et al. Evaluation of the MDRMDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm 2005; 288: 349-59.
17. Dolman DEM, Anderson P, Rollinson C, et al. Characterisation of a new in vitro model of the blood-brain barrier BBB. J Physiol 1997; 505P: 56-7.
18. Hurst RD, Fritz IBF. Properties of an immortalised vascular endothelial glioma cell co-culture model of the blood-brain barrier. J Cell Physiol 1996; 167: 81-8.
19. Lockman PR, Mumper RJ, Khan MA, et al. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002; 28: 1-13.
20. Ambikanadan M, Ganesh S, Aliasgar S. Drug delivery to the central nervous system: a review. J Pharm Pharmaceut Sci 2003; 6: 252-73.
21. Tamargo RJ, Brem H. Drug delivery to the central nervous system: a review. Neurosurg Quat 1992; 2: 259-79.
22. Kreuter J. Nanoparticulate systems for brain delivery for drugs. Adv Drug Del Rev 2001; 47: 65-81.
23. Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate-80-coated poly (butylcyanoacylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drugs to the nanoparticles. Pharm Res 2003; 20: 409-16.
24. Alyaudtin RN, Reichel A, Lobenberg R, et al. Interaction of poly (butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J Drug Target 2001; 9: 209-21.
25. Sun W, Xie C, Wang H, et al. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials 2004; 25: 3065-71.
26. Alyautdin R, Gothier D, Petrov V, et al. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 1995; 41: 44-8.
27. Kreuter J, Alyautdin RN, Kharkevich DA, et al. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995; 674: 171-4
28. Gulyaev AE, Gelperina SE, Skidan IN, et al. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles, Pharm Res 1999; 16: 1564-9.
29. Steiniger SC, Kreuter J, Khalansky AS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 2004; 109: 759-67.
30. Alyautdin RN, Petrov VE, Langer K, et al. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 1997; 14: 325-8.
31. Gulyaev AE, Gelperina SE, Skidan IN, et al. Significant transport of Doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999; 16: 1564-9.
32. Alyautdin RN, Tezikov EB, Ramge P, et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate study. J Microencapsul 1998; 15: 67-74.
33. Friese A, Seiller E, Quack G, et al. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm 2000; 49: 103-9.
34. Das D, Lin S. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J Pharm Sci 2005; 94: 1343-53.
35. ® 2005; 2: 108-19.
36. Venne A, Li S, Mandeville R, et al. Hypersensitizing effect of Pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 1996; 56: 3626-9.
37. Miller DW, Batrakova EV, Waltner TO, et al. Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence of two potential pathways for drug absorption. Bioconjug Chem 1997; 8: 649-57.
38. Batrakova EV, Li S, Miller DW, et al. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res 1999b; 16: 1368-74.
39. Batrakova EV, Miller DW, Li S, et al. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther 2001; 296: 556-62.
40. Batrakova EV, Li S, Alakhov VYU, et al. Selective energy depletion and sensitization of multiple drug resistant cancer cells by pluronic block copolymers. Polymer Prepr 2000; 41: 1639-40.
41. Regev R, Assaraf YG, Eytan GD. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem 1999; 259: 18-24.
42. Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 2008; 130: 98-106
43. Liu MX, Li HF, Luo G, et al. Pharmacokinetics and biodistribution of surface modification polymeric nanoparticles. Arch Pharmacol Res 2008; 31: 547-54.
44. Yu L, Bridgers A, Polli J, et al. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res 1999; 16: 1812-7.
45. Dintaman JM, Silverman JA. Inhibition of p-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999; 16: 1550-6.
46. Kin YW, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005; 26: 2713-22.
47. Xie J, Wang CH. Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of anticancer drug. Pharm Res 2005; 22: 2079-90.
48. rd ed. Oxford New York: University Press 1986.
49. Kotzé AF, Lueßen HL, Leeuw BJ, et al. Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). J Control Release 1998; 51: 35-46.
50. Lopez JE, Peppas NA. Cellular evaluation of insulin transmucosal delivery. J Biomater Sci Polymer Edn 2004; 15: 385-96.
51. Schroder U, Sabel BA. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res 1996; 710: 121-4.
52. Rege BD, Kao JPY, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002; 16: 237-46.
53. Dintaman JM, Silverman JA. Inhibition of p-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999; 16: 1550-6.
54. Agarwal A, Lariya N, Saraogi G, Dubey N, Agrawal H, Agrawal GP. Nanoparticles as novel carrier for brain delivery: a review. Curr Pharm Des 2009; 15(8): 917-25.
55. Debbage P. Targeted drugs and nanomedicine: present and future. Curr Pharm Des 2009; 15(2): 153-72.
56. Kabanov AV, Batrakova EV. New technologies for drug delivery across the blood brain barrier. Curr Pharm Des 2004; 10(12): 1355-63.